Indication
Neuromyelitis Optica
7 clinical trials
5 products
2 drugs
Clinical trial
A Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)Status: Active (not recruiting), Estimated PCD: 2022-03-15
Product
RavulizumabClinical trial
Single-center, Open Label Trial of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active Neuromyelitis Optica Spectrum Disorders (NMOSD)Status: Completed, Estimated PCD: 2018-02-15
Drug
TocilizumabClinical trial
Effectiveness and Safety of Efgartigimod in the Acute Phase of Neuromyelitis Optica Spectrum Disorders-a Multicentric, Controlled, Retrospective, Real-Word StudyStatus: Not yet recruiting, Estimated PCD: 2024-11-05
Product
IVMPClinical trial
A Phase 2/3 Open-Label, Single-Arm Trial to Evaluate the Safety and Activity of Eculizumab in Pediatric Patients With Relapsing Neuromyelitis Optica Spectrum DisorderStatus: Terminated, Estimated PCD: 2023-07-31
Product
EculizumabClinical trial
Clinical and Radiological Outcomes in People With Aquaporin-4 IgG Positive Neuromyelitis Optica Spectrum Disorder Treated With RavulizumabStatus: Not yet recruiting, Estimated PCD: 2026-12-31
Clinical trial
An Open Label, add-on Trial of Cetirizine for Patients With Neuromyelitis OpticaStatus: Completed, Estimated PCD: 2016-02-01
Drug
cetirizineClinical trial
A Study on the Safety and Efficacy of Chimeric Antigen Receptor T Cells in the Treatment of Recurrent/Refractory Neuromyelitis OpticaStatus: Recruiting, Estimated PCD: 2026-04-30
Product
CD19 CAR-T cells